Zur Kurzanzeige

2021-01-15Zeitschriftenartikel DOI: 10.1186/s12985-021-01493-4
Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria
dc.contributor.authorOpaleye, Oluyinka Oladele
dc.contributor.authorAkanbi, Olusola Anuoluwapo
dc.contributor.authorOsundare, Folakemi Abiodun
dc.contributor.authorWang, Bo
dc.contributor.authorAdesina, Olufisayo
dc.contributor.authorSunday, Sola Thomas
dc.contributor.authorAkindele, Abiodun Akeem
dc.contributor.authorKlink, Patrycja
dc.contributor.authorBock, C. Thomas
dc.date.accessioned2021-02-09T10:54:19Z
dc.date.available2021-02-09T10:54:19Z
dc.date.issued2021-01-15none
dc.identifier.other10.1186/s12985-021-01493-4
dc.identifier.urihttp://edoc.rki.de/176904/7759
dc.description.abstractBackground Coinfections of HIV-positive individuals with Hepatitis B and D virus (HBV and HDV) are common and can be associated with rapid liver damage. Several antiretroviral drugs for HIV exhibit anti-HBV effect; however, the selection of HBV drug resistance mutations (DRMs) in individuals under HIV antiretroviral therapy (ART) has been reported but rarely in Nigeria. In this study the HBV/HDV prevalence and HBV DRMs in HIV-positive individuals in Southwestern Nigeria were assessed. Methods Plasma samples collected from 310 HIV-positive individuals including 295 ART-experienced and 15 ART-naïve persons attending the HIV clinic in three south-western states of Nigeria between June 2017 and August 2017 were analysed by ELISA for HBsAg and anti-HDV. The presence of HDV RNA and HBV DNA was analysed by (RT)-PCR followed by sequencing and phylogenetic analyses for genotyping. The HBV reverse transcription (RT) region was amplified and sequenced for the analysis of drug resistance mutations. Results Overall, 16.1% (n = 50/310) of the HIV-positive individuals were positive for HBsAg, most of which were ART-experienced (94.0%; n = 47/50). From the 50 HBsAg-positive samples, 72.0% (n = 36/50) were positive for HBV DNA and 16.0% (n = 8/50) had detectable HDV RNA while 5.6% (n = 2/36) of the HBV-DNA positive samples had anti-HDV total antibodies. Sequences were available for 31/36 of the HBV DNA-positive and 3/8 HDV RNA-positive samples. HBV DNA-positive samples were characterised as HBV genotype E infections exclusively, while HDV genotype 1 was detected in the HDV RNA-positive samples. HBV DRMs V173L, L180M, S202I and M204V/I, which are associated with lamivudine resistance, were detected in 32.2% (n = 10/31) of the HBV DNA-positive samples. Most of these mutations (90.0%; n = 9/10) were present in the ART-experienced cohort. Conclusions This study indicates that HBV/HDV coinfections are common in HIV-positive individuals under ART in Nigeria. Furthermore, a high proportion of HBV DRMs which potentially compromise future treatment options were detected, underscoring the need for HBV screening prior to starting ART. Further studies should be performed to monitor a possible increase in the spread of HDV among populations at risk of HIV and HBV infections.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectHBVeng
dc.subjectHDVeng
dc.subjectHIVeng
dc.subjectCo-infectioneng
dc.subjectDrug resistanceeng
dc.subjectARTeng
dc.subjectNigeriaeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titlePrevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigerianone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/7759-6
dc.identifier.doihttps://doi.org/10.1186/s12985-021-01493-4
dc.identifier.doihttp://dx.doi.org/10.25646/7981
dc.type.versionpublishedVersionnone
local.edoc.container-titleVirology Journalnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01493-4none
local.edoc.container-publisher-nameBMCnone
local.edoc.container-volume18none
local.edoc.container-issue20none
local.edoc.container-reportyear2021none
local.edoc.container-firstpage1none
local.edoc.container-lastpage10none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige